No profile data available.
Valneva SE (VALN) is a healthcare company in the antiviral pharmaceuticals industry, based in Saint-Herblain, France, with about 620 full-time employees.
It reported revenue of 174.66 million EUR for fiscal year 2025, up 3.0% from fiscal year 2024, and net income of -115.19 million EUR. In Q2 2026 (the quarter ended June 30, 2026) revenue was 34.94 million EUR, down 27.7% from a year before. United States was its largest region in fiscal year 2025, with 31% of revenue. Its market capitalization was $548.08 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Valneva reported 174.66 million EUR in revenue for fiscal year 2025, up 3.0% from 169.58 million EUR in fiscal year 2024. In Q2 2026 revenue was 34.94 million EUR.
United States: 31% of revenue by region in fiscal year 2025, followed by Canada (17%).
$548.08 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include BioNTech SE (BNTX), Novavax, Inc. (NVAX), Vir Biotechnology, Inc. (VIR), Assembly Biosciences, Inc. (ASMB).